Liang, Emily C. http://orcid.org/0000-0001-5790-4770
Rejeski, Kai
Fei, Teng
Albittar, Aya
Huang, Jennifer J.
Portuguese, Andrew J. http://orcid.org/0000-0003-1010-4578
Wu, Qian http://orcid.org/0000-0002-2292-4816
Raj, Sandeep
Subklewe, Marion http://orcid.org/0000-0001-9154-9469
Shouval, Roni
Gauthier, Jordan
Article History
Received: 15 February 2024
Revised: 19 March 2024
Accepted: 27 March 2024
First Online: 16 April 2024
Competing interests
: ECL: Glass Health: consultancy. KR: BMS/Celgene: consultancy, honoraria; Novartis: honoraria; Kite/Gilead: research funding, travel support; Pierre-Fabre: travel support. MS: Amgen: research funding, speakers’ bureau; BMS/Celgene: research funding, speakers’ bureau; Gilead: research funding, speakers’ bureau; Janssen: research funding, consultancy, speakers’ bureau; Miltenyi Biotec; research funding, consultancy; Novartis: research funding, consultancy, speakers’ bureau; Roche: research funding, speakers’ bureau; Seattle Genetics: research funding; Takeda: research funding, consultancy, speakers’ bureau; AvenCell: consultancy; CDR-Life: consultancy; Ichnos Sciences: consultancy; Incyte Biosciences: consultancy; Molecular Partners: consultancy; Pfizer: consultancy, speakers’ bureau; AztraZeneca: speakers’ bureau; GSK: speakers’ bureau. JG: Kite Pharma: consultancy, honoraria; MorphoSys: consultancy, research funding; Angiocrine Bioscience: research funding; Century Therapeutics: independent data review committee; Celgene (a Bristol Myers Squibb company): research funding; Legend Biotech: consultancy, honoraria; Janssen: consultancy, honoraria; Juno Therapeutics (a Bristol Myers Squibb company): research funding; Sobi: consultancy, honoraria, research funding. The remaining authors have nothing to declare. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.